Francisco Zamora

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

José Ramón Arribas, Pierre‐Marie Girard, Roland Landman et al. · The Lancet Infectious Diseases · 2015 · 143 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Comparison of the Prognostic Value of Liver Biopsy and FIB-4 Index in Patients Coinfected With HIV and Hepatitis C Virus

Juan Berenguer, Francisco Zamora, Teresa Aldámiz‐Echevarría et al. · Clinical Infectious Diseases · 2014 · 40 citations · Full text

Medicine, Infectious Diseases, Pathology +12

Effects of Sustained Viral Response in Patients With HIV and Chronic Hepatitis C and Nonadvanced Liver Fibrosis

Juan Berenguer, Francisco Zamora, Ana Carrero et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2014 · 30 citations

Medicine, Infectious Diseases, Pharmacotherapy +17

Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy

Ignacio Valero, Alicia González-Baeza, Miriam Estébanez et al. · PLoS ONE · 2013 · 24 citations · Full text

Medicine, Neurology, Pharmacotherapy +16

A Prospective Cohort Study of Neurocognitive Function in Aviremic HIV-Infected Patients Treated With 1 or 3 Antiretrovirals

Ignacio Valero, Alicia González-Baeza, Miriam Estébanez et al. · Clinical Infectious Diseases · 2014 · 19 citations · Full text

Medicine, Neurology, Pharmacotherapy +17